U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H69NO13
Molecular Weight 747.9548
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 18
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLARITHROMYCIN

SMILES

CC[C@]1([H])[C@](C)([C@@]([H])([C@@]([H])(C)C(=O)[C@]([H])(C)C[C@](C)([C@@]([H])([C@@]([H])(C)[C@@]([H])([C@@]([H])(C)C(=O)O1)O[C@@]2([H])C[C@](C)([C@]([H])([C@]([H])(C)O2)O)OC)O[C@@]3([H])[C@@]([H])([C@]([H])(C[C@@]([H])(C)O3)N(C)C)O)OC)O)O

InChI

InChIKey=AGOYDEPGAOXOCK-KCBOHYOISA-N
InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1

HIDE SMILES / InChI

Molecular Formula C38H69NO13
Molecular Weight 747.9548
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 18 / 18
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including www.ncbi.nlm.nih.gov/pubmed/10760175

Clarithromycin is an antibacterial drug which is used either in combination with lansoprazole and amoxicillin (Prevpac), in combination with omeprazole and amoxicillin (Omeclamox) or alone (Biaxin) for the treatment of broad range of infections. The drug exerts its action by binding to 23s rRNA (with nucleotides in domains II and V). The binding leads to the protein synthesis inhibition and the cell death.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.5 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BIAXIN

Approved Use

BIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults.

Launch Date

6.8886718E11
Curative
BIAXIN

Approved Use

BIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults.

Launch Date

6.887808E11
Curative
BIAXIN

Approved Use

BIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults.

Launch Date

6.887808E11
Curative
BIAXIN

Approved Use

BIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults.

Launch Date

6.887808E11
Curative
BIAXIN

Approved Use

BIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults.

Launch Date

6.887808E11
Curative
BIAXIN

Approved Use

BIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults.

Launch Date

6.887808E11
Curative
BIAXIN

Approved Use

BIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults.

Launch Date

6.887808E11
Curative
BIAXIN

Approved Use

BIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults.

Launch Date

6.887808E11
Curative
BIAXIN

Approved Use

BIAXIN is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults; Acute Maxillary Sinusitis; Community-Acquired Pneumonia; Pharyngitis/Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Acute Otitis Media in Pediatric Patients; Treatment and Prophylaxis of Disseminated Mycobacterial Infections; Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults.

Launch Date

6.887808E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.21 mg/L
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CLARITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.09 mg/L
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLARITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
26.81 mg × h/L
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CLARITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.45 mg × h/L
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLARITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.7 h
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CLARITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.9 h
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLARITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
23.1%
500 mg 2 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CLARITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
28.7%
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLARITHROMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
500 mg 2 times / day steady, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: steady
Dose: 500 mg, 2 times / day
Sources:
unhealthy, 33 - 51 years
n = 41
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 33 - 51 years
Sex: M+F
Population Size: 41
Sources:
Other AEs: Taste metallic, Gastrointestinal pain...
Other AEs:
Taste metallic (19 patients)
Gastrointestinal pain (4 patients)
Nausea (5 patients)
Vomiting (3 patients)
Diarrhea (2 patients)
Headache (7 patients)
Sources:
2000 mg 2 times / day steady, oral (max)
Highest studied dose
Dose: 2000 mg, 2 times / day
Route: oral
Route: steady
Dose: 2000 mg, 2 times / day
Sources:
unhealthy, adult
n = 53
Health Status: unhealthy
Condition: HIV disease
Age Group: adult
Sex: unknown
Population Size: 53
Sources:
Other AEs: Abdominal pain, Diarrhea...
Other AEs:
Abdominal pain (7.5%)
Diarrhea (9.4%)
Flatulence (7.5%)
Headache (7.5%)
Nausea (28.3%)
Rash (9.4%)
Taste perversion (18.9%)
Vomiting (24.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Taste metallic 19 patients
500 mg 2 times / day steady, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: steady
Dose: 500 mg, 2 times / day
Sources:
unhealthy, 33 - 51 years
n = 41
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 33 - 51 years
Sex: M+F
Population Size: 41
Sources:
Diarrhea 2 patients
500 mg 2 times / day steady, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: steady
Dose: 500 mg, 2 times / day
Sources:
unhealthy, 33 - 51 years
n = 41
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 33 - 51 years
Sex: M+F
Population Size: 41
Sources:
Vomiting 3 patients
500 mg 2 times / day steady, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: steady
Dose: 500 mg, 2 times / day
Sources:
unhealthy, 33 - 51 years
n = 41
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 33 - 51 years
Sex: M+F
Population Size: 41
Sources:
Gastrointestinal pain 4 patients
500 mg 2 times / day steady, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: steady
Dose: 500 mg, 2 times / day
Sources:
unhealthy, 33 - 51 years
n = 41
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 33 - 51 years
Sex: M+F
Population Size: 41
Sources:
Nausea 5 patients
500 mg 2 times / day steady, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: steady
Dose: 500 mg, 2 times / day
Sources:
unhealthy, 33 - 51 years
n = 41
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 33 - 51 years
Sex: M+F
Population Size: 41
Sources:
Headache 7 patients
500 mg 2 times / day steady, oral
Recommended
Dose: 500 mg, 2 times / day
Route: oral
Route: steady
Dose: 500 mg, 2 times / day
Sources:
unhealthy, 33 - 51 years
n = 41
Health Status: unhealthy
Condition: rheumatoid arthritis
Age Group: 33 - 51 years
Sex: M+F
Population Size: 41
Sources:
Taste perversion 18.9%
2000 mg 2 times / day steady, oral (max)
Highest studied dose
Dose: 2000 mg, 2 times / day
Route: oral
Route: steady
Dose: 2000 mg, 2 times / day
Sources:
unhealthy, adult
n = 53
Health Status: unhealthy
Condition: HIV disease
Age Group: adult
Sex: unknown
Population Size: 53
Sources:
Vomiting 24.5%
2000 mg 2 times / day steady, oral (max)
Highest studied dose
Dose: 2000 mg, 2 times / day
Route: oral
Route: steady
Dose: 2000 mg, 2 times / day
Sources:
unhealthy, adult
n = 53
Health Status: unhealthy
Condition: HIV disease
Age Group: adult
Sex: unknown
Population Size: 53
Sources:
Nausea 28.3%
2000 mg 2 times / day steady, oral (max)
Highest studied dose
Dose: 2000 mg, 2 times / day
Route: oral
Route: steady
Dose: 2000 mg, 2 times / day
Sources:
unhealthy, adult
n = 53
Health Status: unhealthy
Condition: HIV disease
Age Group: adult
Sex: unknown
Population Size: 53
Sources:
Abdominal pain 7.5%
2000 mg 2 times / day steady, oral (max)
Highest studied dose
Dose: 2000 mg, 2 times / day
Route: oral
Route: steady
Dose: 2000 mg, 2 times / day
Sources:
unhealthy, adult
n = 53
Health Status: unhealthy
Condition: HIV disease
Age Group: adult
Sex: unknown
Population Size: 53
Sources:
Flatulence 7.5%
2000 mg 2 times / day steady, oral (max)
Highest studied dose
Dose: 2000 mg, 2 times / day
Route: oral
Route: steady
Dose: 2000 mg, 2 times / day
Sources:
unhealthy, adult
n = 53
Health Status: unhealthy
Condition: HIV disease
Age Group: adult
Sex: unknown
Population Size: 53
Sources:
Headache 7.5%
2000 mg 2 times / day steady, oral (max)
Highest studied dose
Dose: 2000 mg, 2 times / day
Route: oral
Route: steady
Dose: 2000 mg, 2 times / day
Sources:
unhealthy, adult
n = 53
Health Status: unhealthy
Condition: HIV disease
Age Group: adult
Sex: unknown
Population Size: 53
Sources:
Diarrhea 9.4%
2000 mg 2 times / day steady, oral (max)
Highest studied dose
Dose: 2000 mg, 2 times / day
Route: oral
Route: steady
Dose: 2000 mg, 2 times / day
Sources:
unhealthy, adult
n = 53
Health Status: unhealthy
Condition: HIV disease
Age Group: adult
Sex: unknown
Population Size: 53
Sources:
Rash 9.4%
2000 mg 2 times / day steady, oral (max)
Highest studied dose
Dose: 2000 mg, 2 times / day
Route: oral
Route: steady
Dose: 2000 mg, 2 times / day
Sources:
unhealthy, adult
n = 53
Health Status: unhealthy
Condition: HIV disease
Age Group: adult
Sex: unknown
Population Size: 53
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no
no
no
no
no
no
no (co-administration study)
Comment: Administration of CLARITHROMYCIN had no effect on caffeine PK
no
no (co-administration study)
Comment: Administration of CLARITHROMYCIN had no effect on tolbutamide (CYP2C9 probe) PK
no
no (co-administration study)
Comment: Administration of CLARITHROMYCIN had no effect on dextromethorphan (CYP2D6 probe) PK
strong
yes (co-administration study)
Comment: Serious adverse reactions have been reported in patients taking larithromycin concomitantly with CYP3A4 substrates.
weak
yes [IC50 14 uM]
yes [IC50 43.5 uM]
yes [IC50 5.3 uM]
yes [IC50 59 uM]
yes [IC50 61.7 uM]
yes [IC50 8.9 uM]
yes (co-administration study)
Comment: Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in post-marketing surveillance
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Antimicrobial activity of thiamphenicol-glycinate-acetylcysteinate and other drugs against Chlamydia pneumoniae.
2001
Molecular diagnosis of a Mycobacterium chelonae infection.
2001
The successful treatment of prurigo pigmentosa with macrolide antibiotics.
2001
Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals.
2001 Apr
Postoperative proprionibacterium acnes endophthalmitis.
2001 Apr
Plasma and BAL fluid concentrations of antimicrobial peptides in patients with Mycobacterium avium-intracellulare infection.
2001 Apr
Comparative efficacy of new investigational agents against Helicobacter pylori.
2001 Apr
In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria.
2001 Apr
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea.
2001 Apr
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
2001 Apr
Molecular resistance testing of Helicobacter pylori in gastric biopsies.
2001 Apr
Six cases of confluent and reticulated papillomatosis alleviated by various antibiotics.
2001 Apr
Evaluation of the immunomodulatory effects of the macrolide antibiotic, clarithromycin, in female B6C3F1 mice: a 28-day oral gavage study.
2001 Feb
[Eradication therapy of Helicobacter pylori infection].
2001 Feb
[The history of Helicobacter pylori].
2001 Feb
Breakthrough Streptococcus pneumoniae meningitis during clarithromycin therapy for acute otitis media.
2001 Feb
A rare case of osteomyelitis of the sternum in an adult with sickle cell disease.
2001 Feb
Differentiation between reinfection and recrudescence of helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis.
2001 Feb
Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.
2001 Feb
Multicenter study of incidence of Mycobacterium marinum in humans in Spain.
2001 Feb
Mycobacterium abscessus wound infection.
2001 Feb
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
2001 Feb
Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer.
2001 Feb
Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication.
2001 Feb
[Phlebitis due to intravenous administration of macrolide antibiotics. A comparative study of erythromycin versus clarithromycin].
2001 Feb 3
[Acute delirium, probably precipitated by clarithromycin].
2001 Feb 3
Fixed drug eruption due to clarithromycin.
2001 Jan
[Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege].
2001 Jan
Antibiotic susceptibilities of Helicobacter pylori.
2001 Jan
Acute community-acquired pneumonia: current diagnosis and treatment.
2001 Jan
Treatment of canine leproid granuloma syndrome: preliminary findings in seven dogs.
2001 Jan
Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis.
2001 Jan
Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis.
2001 Jan
Pericarditis after allogeneic peripheral blood stem cell transplantation caused by Legionella pneumophila (non-serogroup 1).
2001 Jan-Feb
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
2001 Mar
Clarithromycin and CNS disturbances.
2001 Mar
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.
2001 Mar
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
2001 Mar
Phenotypic consequences of red-white colony type variation in Mycobacterium avium.
2001 Mar
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication.
2001 Mar
Clarithromycin and risk of Clostridium difficile-associated diarrhoea.
2001 Mar
Evaluation of the clinical microbiology profile of moxifloxacin.
2001 Mar 15
What have we learned from pharmacokinetic and pharmacodynamic theories?
2001 Mar 15
Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
2001 Mar 15
[Buruli ulcer in Togo: 21 cases].
2001 Mar 24
[HIV: a guide on management of seropositive patients].
2001 Mar 3
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome.
2001 May
Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species.
2001 May-Jun
Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone.
2001 May-Jun
A multicenter study of the antimicrobial susceptibility of Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis isolated from patients with community-acquired lower respiratory tract infections in 1999 in Portugal.
2001 Spring
Patents

Sample Use Guides

The recommended dosages of clarithromycin tablets for the treatment of mild to moderate infections in adults are: 250 mg or 500 mg every 12 hours for 7–14 days; 500 mg every 8 or 12 hours for 10-14 days (H.pylori, in in combination with lansoprazole/amoxicillin, in combination with omeprazole/amoxicillin or omeprazole); 500 mg every 12 hours (Mycobacterial Infections).
Route of Administration: Oral
The MIC values for clarithromycin were: 0.12-0.5 ug/ml (Staphylococcus aureus ATCC 29213), 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619), 4-16 ug/ml (Haemophilus influenzae ATCC 49247), 0.015-0.12 ug/ml (Helicobacter pylori ATCC 43504), 1-4 ug/ml (M. avium ATCC 700898).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:01:09 UTC 2021
Edited
by admin
on Fri Jun 25 21:01:09 UTC 2021
Record UNII
H1250JIK0A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLARITHROMYCIN
EP   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
CLARITHROMYCIN [MI]
Common Name English
6-O-METHYLERYTHROMYCIN
Common Name English
CLARITHROMYCIN [MART.]
Common Name English
NAXY
Brand Name English
CLARITHROMYCIN COMPONENT OF PREVPAC
Common Name English
CLARITHROMYCIN IDENTITY [USP-RS]
Common Name English
CLARITHROMYCIN [USP MONOGRAPH]
Common Name English
CLARITHROMYCIN [INN]
Common Name English
CLARITHROMYCIN [WHO-DD]
Common Name English
PREVPAC COMPONENT CLARITHROMYCIN
Common Name English
BIAXIN
Brand Name English
CLAROSIP
Brand Name English
ABBOTT-56268
Code English
MACLADIN
Brand Name English
KLARICID
Brand Name English
CLARITHROMYCIN [EP MONOGRAPH]
Common Name English
ZECLAR
Brand Name English
TE-031
Code English
VECLAM
Brand Name English
CLARITHROMYCIN [VANDF]
Common Name English
CYLLIND
Brand Name English
A-56268
Code English
NSC-758704
Code English
CLARITHROMYCIN [JAN]
Common Name English
CLARITHROMYCIN [USP]
Common Name English
MAVID
Brand Name English
CLARITHROMYCIN IDENTITY
USP-RS  
Common Name English
ERYTHROMYCIN, 6-O-METHYL-
Common Name English
CLARITHROMYCIN [USP-RS]
Common Name English
KLACID
Brand Name English
CLARITHROMYCIN [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
WHO-ATC A02BD09
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-ATC A02BD07
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-VATC QA02BD05
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
FDA ORPHAN DRUG 770820
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-VATC QJ01FA09
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
NDF-RT N0000007529
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-VATC QA02BD04
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-ATC J01FA09
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
NDF-RT N0000007529
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
FDA ORPHAN DRUG 338811
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
NDF-RT N0000007529
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
LIVERTOX 214
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-ATC A02BD05
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-ATC A02BD06
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-VATC QA02BD06
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
NDF-RT N0000175935
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-VATC QA02BD07
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-ATC A02BD04
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
WHO-ATC A02BD11
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
NCI_THESAURUS C261
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
Code System Code Type Description
MERCK INDEX
M3608
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY Merck Index
USP_CATALOG
1134379
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY USP-RS
NDF-RT
N0000190114
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
NDF-RT
N0000182141
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
HSDB
8055
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
ChEMBL
CHEMBL1741
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY P-Glycoprotein Inhibitors [MoA]
CAS
81103-11-9
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
DRUG BANK
DB01211
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
EPA CompTox
81103-11-9
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
NCI_THESAURUS
C1054
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
INN
6252
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
FDA UNII
H1250JIK0A
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
LACTMED
Clarithromycin
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
WIKIPEDIA
CLARITHROMYCIN
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
RXCUI
21212
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
668
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
EVMPD
SUB06641MIG
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
MESH
D017291
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
USP_CATALOG
1134390
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY USP-RS
PUBCHEM
84029
Created by admin on Fri Jun 25 21:01:09 UTC 2021 , Edited by admin on Fri Jun 25 21:01:09 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
POTENT
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: H. INFLUENZAE

Biological Half-life PHARMACOKINETIC 14-OH-CLARITHROMYCIN

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: S. AUREUS

Tmax PHARMACOKINETIC FORMULATION: EXTENDED RELEASE

MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: S. PYOGENES, S. PNEUMONIAE, H. PYLORI

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: H. INFLUENZAE

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: S. AUREUS

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: S. PYOGENES, S. PNEUMONIAE

MIC BIOLOGICAL PATHOGEN: S. PYOGENES, S. PNEUMONIAE, H. PYLORI

SUSCEPTIBILITY: SUSCEPTIBLE

ORAL BIOAVAILABILITY PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC FORMULATION: IMMEDIATE RELEASE

MIC BIOLOGICAL PATHOGEN: S. AUREUS

SUSCEPTIBILITY: RESISTANT

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: H. INFLUENZAE